8-K: Marker Therapeutics Reports Positive Early Results in Lymphoma Trial and Provides Q1 2024 Financial Update

Marker Therapeutics announced encouraging preliminary results from its Phase 1 APOLLO study of MT-601 in lymphoma patients, along with its first quarter 2024 financial results.

Summary

• Marker Therapeutics reported its first quarter 2024 financial results and provided updates on its clinical programs.
• The company's lead program, MT-601, showed promising results in a Phase 1 APOLLO study for lymphoma patients, with three out of three patients at City of Hope demonstrating objective responses.
• One patient with diffuse large B cell lymphoma achieved a complete response that has been maintained for nine months after treatment with MT-601.
• Another patient with transformed follicular Non-Hodgkins Lymphoma also achieved a complete response, which remains three months following treatment.
• A third patient with DLBCL achieved a partial response with all lesions decreasing in size.
• The company received approval for the nonproprietary name neldaleucel for MT-601.
• Marker Therapeutics also has an Investigational New Drug application cleared for MT-601 in pancreatic cancer, but further clinical advancement is pending additional funding.
• The company discontinued the patient-specific part of its Acute Myeloid Leukemia program to focus on an off-the-shelf product, MT-401-OTS, which has received Orphan Drug Designation from the EMA and FDA.
• Marker had $11.3 million in cash and cash equivalents at the end of March 2024, which is expected to fund operations into the fourth quarter of 2025.
• Research and development expenses were $2.6 million for the quarter, down from $3.4 million in the same period last year.
• General and administrative expenses were $1.2 million, down from $2.2 million in the same period last year.
• The company reported a net loss of $2.4 million for the quarter, compared to a net loss of $4.9 million for the same period last year.

Sentiment

Score: 8

Explanation: The document is very positive due to the promising clinical results, reduced operating expenses, and improved net loss. The company's cash runway is also a positive factor. However, the need for additional funding for the pancreatic program and the discontinuation of the patient-specific AML program temper the overall sentiment slightly.

Positives

• The MT-601 lymphoma trial showed very promising early results with complete and partial responses observed in all patients treated at City of Hope.
• The company has secured a non-proprietary name for MT-601, neldaleucel, which is a positive step for regulatory approval.
• The company's cash position is strong enough to fund operations into the fourth quarter of 2025.
• The company has reduced its operating expenses in both R&D and G&A compared to the same quarter last year.
• The net loss for the quarter has significantly decreased compared to the same period last year.

Negatives

• The clinical advancement of MT-601 in pancreatic cancer is pending additional financial support.
• The company discontinued the patient-specific part of its Acute Myeloid Leukemia program, which may be seen as a setback in that area.
• The company is still operating at a loss, although the loss has decreased.

Risks

• The company's ability to secure additional funding for the pancreatic cancer program is a risk.
• The company's reliance on non-dilutive funding sources may limit its ability to rapidly advance its clinical programs.
• Clinical trial results may not continue to be positive as the trials progress.
• The company is still operating at a loss and may need to raise additional capital in the future.

Future Outlook

The company expects to report further data from the Phase 1 APOLLO trial in the second half of 2024 and anticipates initiating the clinical program for MT-401-OTS in the second half of 2024. The company believes its existing cash will fund operations into the fourth quarter of 2025.

Management Comments

• We are pleased to report a strong start to the first quarter of 2024, marked by continued advances in our clinical programs, said Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics.
• Building on our positive results, we continue to observe objective responses in our Phase 1 APOLLO study investigating MT-601 in patients with lymphoma who have relapsed or are ineligible for CAR T therapy.
• Having made these steady advances, we are confident that we are well positioned to achieve our nearand long-term goals related to MT-601 in patients with lymphoma, concluded Dr. Vera.

Industry Context

The announcement highlights the growing interest in T-cell based immunotherapies for cancer treatment, particularly in areas where CAR T-cell therapies have limitations. The company's focus on non-genetically modified T-cells is a differentiator in the competitive landscape of immuno-oncology.

Comparison to Industry Standards

• The complete response rate observed in the MT-601 trial is very encouraging compared to typical outcomes in relapsed/refractory lymphoma patients, especially those who have failed CAR T-cell therapy.
• Companies like Kite Pharma (Yescarta) and Bristol Myers Squibb (Breyanzi) have established CAR T-cell therapies, but Marker's approach with multiTAA-specific T cells offers a potential alternative with reduced toxicities and manufacturing costs.
• The durability of the responses observed in the MT-601 trial, with one patient maintaining a complete response for nine months, is a key differentiator compared to some CAR T-cell therapies where relapse is a significant concern.
• The company's focus on an off-the-shelf product for AML (MT-401-OTS) aligns with industry trends towards more accessible and scalable cell therapies, similar to efforts by companies like Fate Therapeutics.

Stakeholder Impact

• Shareholders will likely react positively to the promising clinical results and improved financial performance.
• Employees may be encouraged by the progress of the company's clinical programs.
• Patients with lymphoma may benefit from the potential of MT-601 as a new treatment option.
• The company's focus on operational excellence and financial resource preservation may reassure creditors and suppliers.

Next Steps

• The company will continue enrolling patients in the Phase 1 APOLLO trial.
• The company expects to report further data from the APOLLO study in the second half of 2024.
• The company anticipates initiating the clinical program for MT-401-OTS in the second half of 2024.
• The company will seek additional financial support for the clinical advancement of MT-601 in pancreatic cancer.

Key Dates

Keywords

MT-601, neldaleucel, lymphoma, immunotherapy, T cell therapy, cancer, clinical trial, APOLLO study, MT-401-OTS, AML, MDS, biotechnology, oncology